Kipourou Maria, Begou Olga, Manika Katerina, Ismailos Georgios, Kontou Paschalina, Pitsiou Georgia, Gika Helen, Kioumis Ioannis
Pulmonary Department, 424 General Military Hospital, 56429 Thessaloniki, Greece.
Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Antibiotics (Basel). 2023 Feb 2;12(2):307. doi: 10.3390/antibiotics12020307.
We aimed to evaluate the pharmacokinetic profile of tigecycline in plasma and its penetration to sputum in moderately ill patients with an infectious acute exacerbation of chronic obstructive pulmonary disease (COPD).
Eleven patients hospitalized with acute respiratory failure due to an acute COPD exacerbation with clinical evidence of an infectious cause received tigecycline 50 mg twice daily after an initial loading dose of 100 mg. Blood and sputum samples were collected at steady state after dose seven.
In plasma, mean C pl was 975.95 ± 490.36 ng/mL and mean C pl was 214.48 ±140.62 ng/mL. In sputum, mean C was 641.91 ± 253.07 ng/mL and mean C was 308.06 ± 61.7 ng/mL. In plasma, mean AUC was 3765.89 ± 1862.23 ngh/mL, while in sputum mean AUC was 4023.27 ± 793.37 ngh/mL. The mean penetration ratio for the 10/11 patients was 1.65 ± 1.35. The mean Free AUC/MIC ratio for and was 25.10 ± 12.42 and 6.02 ± 2.97, respectively.
Our findings support the clinical effectiveness of tigecycline against commonly causative bacteria in COPD exacerbations and highlight its sufficient lung penetration in pulmonary infections of moderate severity.
我们旨在评估替加环素在中度慢性阻塞性肺疾病（COPD）急性加重期且伴有感染的患者血浆中的药代动力学特征及其在痰液中的渗透情况。
11例因COPD急性加重导致急性呼吸衰竭且有感染病因临床证据的住院患者，在初始负荷剂量100mg后，每日两次接受50mg替加环素治疗。在第7剂给药后稳态时采集血液和痰液样本。
在血浆中，平均Cpl为975.95±490.36ng/mL，平均Cpl为214.48±140.62ng/mL。在痰液中，平均C为641.91±253.07ng/mL，平均C为308.06±61.7ng/mL。在血浆中，平均AUC为3765.89±1862.23ngh/mL，而在痰液中平均AUC为4023.27±793.37ngh/mL。10/11例患者的平均渗透比为1.65±1.35。和的平均游离AUC/MIC比值分别为25.10±12.42和6.02±2.97。
我们的研究结果支持替加环素对COPD加重期常见致病菌的临床有效性，并突出了其在中度严重肺部感染中足够的肺组织渗透能力。
